| Literature DB >> 26184493 |
Alimuddin Zumla1, Markus Maeurer2, Jeremiah Chakaya3, Michael Hoelscher4, Francine Ntoumi5, Roxana Rustomjee6, Cristina Vilaplana7, Dorothy Yeboah-Manu8, Voahangy Rasolof9, Paula Munderi10, Nalini Singh11, Eleni Aklillu12, Nesri Padayatchi13, Eusebio Macete14, Nathan Kapata15, Modest Mulenga16, Gibson Kibiki17, Sayoki Mfinanga18, Thomas Nyirenda19, Leonard Maboko20, Alberto Garcia-Basteiro14, Niaina Rakotosamimanana9, Matthew Bates15, Peter Mwaba15, Klaus Reither21, Sebastien Gagneux21, Sarah Edwards22, Elirehema Mfinanga23, Salim Abdulla24, Pere-Joan Cardona7, James B W Russell25, Vanya Gant26, Mahdad Noursadeghi1, Paul Elkington27, Maryline Bonnet28, Clara Menendez29, Tandakha N Dieye30, Bassirou Diarra31, Almoustapha Maiga31, Abraham Aseffa32, Shreemanta Parida2, Christian Wejse33, Eskild Petersen33, Pontiano Kaleebu10, Matt Oliver34, Gill Craig35, Tumena Corrah36, Leopold Tientcheu37, Martin Antonio37, Martin Rao2, Timothy D McHugh38, Aziz Sheikh39, Giuseppe Ippolito40, Gita Ramjee41, Stefan H E Kaufmann42, Gavin Churchyard43, Andrie Steyn44, Martin Grobusch45, Ian Sanne46, Neil Martinson47, Rajhmun Madansein48, Robert J Wilkinson49, Bongani Mayosi50, Marco Schito51, Robert S Wallis43.
Abstract
The treatment of tuberculosis is based on combinations of drugs that directly target Mycobacterium tuberculosis. A new global initiative is now focusing on a complementary approach of developing adjunct host-directed therapies.Entities:
Mesh：
Substances：
Year: 2015 PMID： 26184493 DOI： 10.1038/nrd4696
Source DB: PubMed Journal: Nat Rev Drug Discov ISSN： 1474-1776 Impact factor: 84.694